Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancersNEW HAVEN, Conn., Oct.

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Merck & Co/MSD has won approval in ... as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.

The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional ...

Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Oct 2024 - Immutep (ASX:IMM) has made significant progress over the past year with its lead immunotherapy candidate, eftilagimod alpha (efti).

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

MSD is collaborating with hospitals in Hanoi and Ho Chi Minh City to hold a series of seminars on triple-negative breast ...